Pharma Firms Urged To Push For Post-Brexit Regulatory Equivalence Deal
A mutual recognition agreement between the UK and EU on equivalence of regulatory procedures and processes could provide pharmaceutical companies with some stability and continuity post-Brexit – and save them some money.
You may also be interested in...
Japan Issues Strong Warning Over Brexit
Uncertainty is bad for business and can deter investment, warns Japan in relation to eventual talks on the UK’s exit from the EU. Japan’s preferred Brexit outcome? For the UK to keep both EU law and the European Medicines Agency.
Brazilian Regulator Extends COVID-19 Measures
Brazil’s medicines regulator is extending COVID-19 era resolutions designed to speed up its evaluation of clinical research in Brazil.
Canada Publishes Real World Evidence Guidance For HTA And Regulatory Decision Making
The new guidance was drawn up through extensive engagement with national and international experts in RWD and RWE, as well as stakeholders in Canada.